Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0HHTKX
ADC Name
CD33 PNU ADC4-2
Synonyms
CD33-PNU-ADC4-2
   Click to Show/Hide
Organization
Genentech, Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Acute myeloid leukaemia [ICD11:2A60]
Investigative
Drug-to-Antibody Ratio
3-4
Structure
Antibody Name
Anti-CD33 mAb 15G15.33
  Antibody Info 
Antigen Name
Myeloid cell surface antigen CD33 (CD33)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
CD33 PNU ADC4-2 linker
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.6
ng/mL
EoL-1 cells
Chronic eosinophilic leukemia
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.60 ng/mL Positive CD33 expression (CD33+++/++)
Method Description
The cells, at a predeterminedconcentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5CO2, serialdilutions of each test article (TA) were added to the cells. Cells were incubated with test articlesfor 72 hours, and viability was detected with CellTiter-Glo reagent.
In Vitro Model Chronic eosinophilic leukemia EoL-1 cells CVCL_0258
References
Ref 1 Peptidomimetic compounds and antibody-drug conjugates thereof; 2015-09-03.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.